Spinnaker Trust bought a new stake in shares of Novartis AG (NYSE:NVS – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,759 shares of the company’s stock, valued at approximately $202,000.
Other large investors have also modified their holdings of the company. Founders Financial Securities LLC grew its position in Novartis by 3.4% during the 2nd quarter. Founders Financial Securities LLC now owns 2,832 shares of the company’s stock worth $301,000 after purchasing an additional 94 shares during the period. Steigerwald Gordon & Koch Inc. boosted its stake in shares of Novartis by 4.8% in the third quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock worth $241,000 after buying an additional 95 shares during the last quarter. NBC Securities Inc. grew its holdings in Novartis by 0.9% during the second quarter. NBC Securities Inc. now owns 10,492 shares of the company’s stock worth $1,116,000 after acquiring an additional 97 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Novartis by 5.1% during the first quarter. EverSource Wealth Advisors LLC now owns 2,013 shares of the company’s stock worth $196,000 after acquiring an additional 98 shares during the period. Finally, Portside Wealth Group LLC raised its position in Novartis by 3.4% during the second quarter. Portside Wealth Group LLC now owns 3,000 shares of the company’s stock valued at $319,000 after acquiring an additional 99 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.
Novartis Stock Performance
NVS opened at $106.81 on Thursday. The company has a market cap of $218.32 billion, a price-to-earnings ratio of 12.41, a PEG ratio of 1.61 and a beta of 0.58. The firm’s fifty day simple moving average is $115.11 and its two-hundred day simple moving average is $109.55. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on NVS. Bank of America cut shares of Novartis from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $135.00 to $130.00 in a research note on Wednesday, September 11th. The Goldman Sachs Group reissued a “neutral” rating and set a $121.00 price target (up from $119.00) on shares of Novartis in a report on Thursday, September 5th. Jefferies Financial Group cut shares of Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, September 3rd. BMO Capital Markets increased their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Novartis in a research report on Friday, July 19th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $121.50.
Check Out Our Latest Research Report on Novartis
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Featured Articles
- Five stocks we like better than Novartis
- What is the Euro STOXX 50 Index?
- What a Trump Win Looks Like for the Market Now and Into 2025
- Best Stocks Under $5.00
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- How to Calculate Inflation Rate
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.